S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Cardiovascular Systems Stock Forecast, Price & News

-0.92 (-2.18 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $41.37
50-Day Range
MA: $44.13
52-Week Range
Now: $41.37
Volume139,524 shs
Average Volume233,818 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Cardiovascular Systems logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:CSII
Year FoundedN/A



Sales & Book Value

Annual Sales$236.54 million
Book Value$7.62 per share


Net Income$-27,240,000.00


Market Cap$1.66 billion
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.48 out of 5 stars

Medical Sector

461st out of 1,957 stocks

Surgical & Medical Instruments Industry

46th out of 168 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.92 (-2.18 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CSII News and Ratings via Email

Sign-up to receive the latest news and ratings for CSII and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

Is Cardiovascular Systems a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Cardiovascular Systems?

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Cardiovascular Systems

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) released its quarterly earnings data on Wednesday, November, 4th. The medical device company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.18. The medical device company earned $60.54 million during the quarter, compared to analyst estimates of $56.27 million. Cardiovascular Systems had a negative net margin of 10.12% and a negative trailing twelve-month return on equity of 11.43%.
View Cardiovascular Systems' earnings history

How has Cardiovascular Systems' stock price been impacted by COVID-19 (Coronavirus)?

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CSII shares have increased by 13.9% and is now trading at $41.37.
View which stocks have been most impacted by COVID-19

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems updated its third quarter 2021 After-Hours earnings guidance on Wednesday, February, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $69.27 million.

What price target have analysts set for CSII?

7 Wall Street analysts have issued 12-month price targets for Cardiovascular Systems' stock. Their forecasts range from $45.00 to $50.00. On average, they anticipate Cardiovascular Systems' share price to reach $47.43 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts' price targets for Cardiovascular Systems
or view top-rated stocks among Wall Street analysts.

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the following people:
  • Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 61, Pay $1.17M)
  • Mr. Jeffrey S. Points, Chief Financial Officer (Age 44, Pay $507.49k)
  • Ms. Rhonda J. Robb, Chief Operating Officer (Age 53, Pay $830.22k)
  • Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 49, Pay $523.26k)
  • Dr. Ryan D. Egeland M.D., Ph.D., Chief Medical Officer (Age 46, Pay $490.64k)
  • Mr. John E. Nielsen, VP of Investor Relations & Corp. Communications
  • Ms. Sandra M. Sedo, Chief Compliance Officer (Age 57)
  • Mr. David S. Whitescarver, VP of Corp. Devel. & Intellectual Property (Age 63)
  • Mr. Stephen J. Rempe, Chief HR Officer (Age 48)

What is Scott Ward's approval rating as Cardiovascular Systems' CEO?

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Who are some of Cardiovascular Systems' key competitors?

What other stocks do shareholders of Cardiovascular Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.37%), Brown Capital Management LLC (14.90%), Janus Henderson Group PLC (3.41%), Renaissance Technologies LLC (3.18%), New York State Common Retirement Fund (1.97%) and Northern Trust Corp (1.30%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb and Sandra Sedo.
View institutional ownership trends for Cardiovascular Systems

Which major investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Peregrine Capital Management LLC, Aviva PLC, Frontier Capital Management Co. LLC, Rice Hall James & Associates LLC, Comerica Bank, Squarepoint Ops LLC, and Barclays PLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems
or view top insider-selling stocks.

Which major investors are buying Cardiovascular Systems stock?

CSII stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Morgan Stanley, Walleye Capital LLC, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Canada Pension Plan Investment Board, and Exchange Traded Concepts LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, and Rhonda J Robb.
View insider buying and selling activity for Cardiovascular Systems
or or view top insider-buying stocks.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $41.37.

How much money does Cardiovascular Systems make?

Cardiovascular Systems has a market capitalization of $1.66 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Cardiovascular Systems have?

Cardiovascular Systems employs 779 workers across the globe.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is www.csi360.com.

Where are Cardiovascular Systems' headquarters?

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.